EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 36 / No 2 (Février 2020) Med Sci (Paris), 36 2 (2020) 137-140 References
Open Access
Issue
Med Sci (Paris)
Volume 36, Number 2, Février 2020
Page(s) 137 - 140
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020010
Published online 04 March 2020
  1. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy : a literature review. Orphanet J Rare Dis 2017 ; 12 : 124. [CrossRef] [PubMed] [Google Scholar]
  2. Roberts DF, Chavez J, Court SD. The genetic component in child mortality. Arch Dis Child 1970 ; 45 : 33–38. [CrossRef] [PubMed] [Google Scholar]
  3. Kolb SJ, Kissel JT. 2011, Spinal muscular atrophy: a timely review. Arch Neurol 2011 ; 68 : 8 979–984. [CrossRef] [PubMed] [Google Scholar]
  4. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995 ; 80 : 155–165. [CrossRef] [PubMed] [Google Scholar]
  5. Monani UR. Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron 2005 ; 48 : 885–896. [CrossRef] [PubMed] [Google Scholar]
  6. Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002 ; 4 : 20–26. [CrossRef] [PubMed] [Google Scholar]
  7. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008 ; 16 : 1648–1656. [CrossRef] [PubMed] [Google Scholar]
  8. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009 ; 17 : 1187–1196. [CrossRef] [PubMed] [Google Scholar]
  9. Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011 ; 20 : 681–693. [CrossRef] [PubMed] [Google Scholar]
  10. Le TT, Butchbach LT, Zhang ME, et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 2005 ; 14 : 845–857. [CrossRef] [PubMed] [Google Scholar]
  11. Barkats M. Widespread gene delivery to motor neurons using peripheral injection of AAV vectors (US2019153474 (A1). May 10, 2007. [Google Scholar]
  12. Foust KD, Nurre E, Montgomery CL, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009 ; 27 : 59–65. [CrossRef] [PubMed] [Google Scholar]
  13. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010 ; 28 : 271–274. [CrossRef] [PubMed] [Google Scholar]
  14. Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 2011; 19 ( : 1971–80. [CrossRef] [PubMed] [Google Scholar]
  15. Gray SJ, Matagne V, Bachaboina L, et al. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011 ; 19 : 1058–1069. [CrossRef] [PubMed] [Google Scholar]
  16. Nau JY. À quel prix le Zolgensma®, le médicament le plus cher du monde, sera-t-il vendu en France ? Slate 2019. http://www.slate.fr/story/178845/sante-medicaments-zolgensma-novartis-avexis-fixation-prix-transparence. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.